BioSpace News Archive

CARsgen Therapeutics, a clinical-stage biopharmaceutical company, announced updated safety and efficacy results from its ongoing global clinical studies of CT053, an investigational chimeric antigen receptor T-cell therapy for patients with relapsed and/or refractory multiple myeloma.

Separate analyses provide insight into the characteristics of patients who respond long-term and management of drug-related rash

Amphivena Therapeutics, a clinical-stage oncology company focused on developing immunotherapeutics that restore anti-cancer immunity in patients, presented data on a novel assay for selection of acute myeloid leukemia patients for treatment with AMV564, at the 62nd Annual American Society of Hematology Meeting and Exposition, taking place virtually from December 5-8, 2020.

67% spleen volume response rate observed in 63 first-line myelofibrosis patients treated with CPI-0610 + ruxolitinib at 24 weeks

Cardiff Oncology, Inc., a clinical-stage biotechnology company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, castration-resistant prostate cancer and leukemia, announced the presentation of updated data from its Phase 1b/2 study in relapsed/refractory acute myeloid leukemia.

MRD assessment with clonoSEQ improves outcomes both for patients and the healthcare system, as patients with undetectable MRD may be able to discontinue active treatment

BioCryst Pharmaceuticals, Inc. announced that preclinical data on BCX9930, an oral Factor D inhibitor under development as monotherapy for paroxysmal nocturnal hemoglobinuria and other complement-mediated diseases, showed complete in vitro blockade of both hemolysis of PNH erythrocytes and accumulation of C3 fragments on PNH erythrocytes, indicating that BCX9930 monotherapy has the potential to inhibit both intravascular and extravascular hemolysis.

Data demonstrate potential to differentiate between the two major forms of amyloidosis - ATTR and AL - and non invasive detection of systemic AL amyloidosis in multiple organ systems

Preliminary Data from First Patient Demonstrates Initial Safety and Tolerability of RP-L301, Near Doubling of Hemoglobin to Normal Range and Additional Normalization of Hemolysis Markers

Early multi-center results indicate that Orca-T, a novel approach to HSCT,improves time-to-engraftment, markedly reducesthe incidence and severity of GvHD, and significantly improved GRFS at 1 year